Nautilus Biotechnology Inc

NASDAQ NAUT

Data sourced from

and

Download Data

Nautilus Biotechnology Inc Operating Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2024: -0.13

Nautilus Biotechnology Inc Operating Cash Flow Per Share is -0.13 for the Trailing 12 Months (TTM) ending March 31, 2024, a -40.88% change year over year. Operating cash flow per share represents the amount of cash generated from a company's core operations per outstanding share. It is calculated by dividing the operating cash flow by the weighted average number of basic shares outstanding. This metric provides insights into the company's ability to generate cash flow from its day-to-day operations on a per-share basis. It is useful for evaluating the company's cash flow generation and comparing it with other companies on a per-share basis.

Nautilus Biotechnology Inc Operating Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was -0.09, a 17.73% change year over year.
Nautilus Biotechnology Inc Operating Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.11, a -28.04% change year over year.
Nautilus Biotechnology Inc Operating Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was -0.09, a -1,245.90% change year over year.
Nautilus Biotechnology Inc Operating Cash Flow Per Share for the Trailing 12 Months (TTM) ending March 31, 2020 was -0.01, a 99.92% change year over year.

NASDAQ: NAUT

Nautilus Biotechnology Inc

CEO	Mr. Sujal M. Patel
IPO Date	June 10, 2021
Location	United States
Headquarters	2701 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	163
Sector	Healthcare
Industry	Biotechnology

Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Key trends